Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: SDR-SI who wrote (774)	10/26/1998 8:13:00 AM
From: Harold Engstrom	Read Replies (2) \| Respond to of 1686

Hirulog. I remember back in 1994 when Biogen decided not to continue pursuing this compound. The data showed it was better than heparin, but only marginally so. It was also much more expensive. It had the advantage of not having its effectiveness decline quickly like heparin (which has a half-life of 5 minutes). It also has the advantage of being uniform enough to potentially serve to coat products (something my dad looked into). I am surprised that approval is delayed because it seems like something maybe the market should decide about - it seems to have a good safety profile and to be effective even though it is so expensive to use.